Acadia Pharmaceuticals Inc Dossier - Source-backed chat

Acadia Pharmaceuticals Inc

ACADNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.90

Intrinsic Value $20.81median of 5 methods · middle span $15-$29based on filings through 30 Jun 2026

Market Price $20.15Price as of 30 Sep 2026

Near fair valueIntrinsic value is 3% above the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

Data confidence Sign in to view data confidence

Market Cap $3.5B

Enterprise Value $3.1B

Shares Outstanding 174.6M diluted

Moat Rating None

Next Earnings Date4 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Acadia Pharmaceuticals presents a compelling investment opportunity as a commercial-stage central nervous system (CNS) biotech trading at an attractive valuation relative to its established revenue base. The company's commercial engine is anchored by two growing franchises: NUPLAZID (for Parkinson's disease psychosis) and DAYBUE (for Rett syndrome), which are guided to generate substantial combined revenues. While near-term profitability has been compressed by commercial investments (such as the 30% sales force expansion and the launch of DAYBUE STIX), Acadia's strong balance sheet with over $851 million in cash provides significant financial flexibility. The upcoming Phase 2 topline data for remlifanserin (ACP-204) in Alzheimer's disease psychosis represents a major high-upside clinical catalyst that could unlock a multi-billion dollar market opportunity.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets20 analysts · as of 18 Aug 2026

Low · most bearish analyst$17.00

Mean target$33.85

High · most bullish analyst$49.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$17.00

DAYBUE persistency issues persist and the STIX formulation fails to attract significant new or returning patients, leading to a sales miss. The Phase 2 remlifanserin trial fails to meet its primary efficacy endpoint or reveals safety/tolerability concerns in the elderly population, wiping out a key pipeline driver. Additionally, the EMA CHMP maintains its negative opinion on trofinetide, permanently blocking European market entry and limiting long-term growth options.

Base CaseCentral scenario

$33.85

Matches the consensus mean

Acadia successfully executes on its 2026 financial guidance, delivering total revenues of $1.22 to $1.28 billion. DAYBUE STIX adoption stabilizes the Rett syndrome franchise, offsetting liquid formulation discontinuations. NUPLAZID maintains mid-single-digit growth. The Phase 2 remlifanserin data shows positive trends or a modest win, justifying progression into Phase 3 trials, while European regulatory hurdles for trofinetide are gradually addressed through the re-examination process.

Bull CaseUpside scenario

$49.00

DAYBUE STIX launch accelerates patient acquisition and improves persistency, driving DAYBUE sales to the high end of 2026 guidance ($490 million) and beyond. NUPLAZID continues steady growth, exceeding $790 million. Crucially, the Phase 2 trial of remlifanserin (ACP-204) in Alzheimer's disease psychosis delivers a clear, statistically significant efficacy win with a clean safety profile, positioning it as a multi-billion dollar blockbuster asset and driving substantial multiple expansion.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Strong commercial foundation with two FDA-approved CNS products generating over $1 billion in annual run-rate revenue.
Robust balance sheet with $851 million in cash, cash equivalents, and investment securities as of Q1 2026, providing a strong runway without dilutive financing risk.
High-impact near-term clinical catalyst with Phase 2 remlifanserin (ACP-204) data in Alzheimer's disease psychosis expected in late Q3 2026.
Launch of DAYBUE STIX provides a more flexible dosing option that could improve patient compliance and expand the addressable Rett syndrome market.

Key Investment Risks

High commercial concentration and dependence on the continued market uptake and persistency of DAYBUE and NUPLAZID.
Clinical development risk, particularly with the upcoming Phase 2 remlifanserin readout, where historical trials in Alzheimer's psychosis have faced high failure rates.
Regulatory setbacks, such as the negative CHMP opinion in Europe for trofinetide, which limits international expansion opportunities.
Compressed near-term profitability due to elevated SG&A expenses from commercial scaling and sales force expansion.

Thesis Invalidation Triggers

Failure of the Phase 2 remlifanserin (ACP-204) trial to meet its primary efficacy endpoint in Alzheimer's disease psychosis.
A significant downward revision in full-year 2026 revenue guidance for either NUPLAZID or DAYBUE.
Definitive rejection of trofinetide by the EMA following the formal re-examination process, eliminating European launch prospects.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.